Daewon Pharmaceutical Co., Ltd. (003220.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	614.8B	605.6B	598.2B	527.0B	478.9B
Cost of Revenue	338.7B	339.3B	310.8B	272.7B	240.9B
Gross Profit	275.9B	266.1B	287.3B	254.2B	237.9B
Operating Expenses
R&D Expense	24.6B	23.8B	21.9B	18.2B	19.5B
SG&A Expense	160.3B	122.0B	119.3B	94.2B	99.6B
General & Admin Expense	24.7B	34.5B	34.3B	22.2B	41.3B
Selling & Marketing Expense	104.9B	87.5B	84.9B	72.0B	58.3B
Other Expenses	97.6B	116.9B	117.9B	112.6B	95.3B
Total Operating Expenses	276.0B	262.6B	259.1B	222.0B	194.9B
Cost and Expenses	615.0B	602.2B	569.9B	494.7B	435.9B
Operating Income (EBIT)	(66.7M)	3.5B	28.2B	32.2B	43.0B
Non-Operating
Interest Income	1.1B	1.1B	1.5B	1.3B	1.1B
Interest Expense	6.8B	7.2B	9.3B	4.6B	3.7B
Net Interest Income	(5.6B)	(6.1B)	(7.8B)	(3.3B)	(2.6B)
Other Non-Op Income/Expense	9.2B	(734.0M)	(13.0B)	(6.4B)	(4.3B)
Non-Operating Income (excl Interest)	(7.6B)	(6.3B)	2.8B	1.8B	601.4M
EBT (Pre-Tax Income)	9.1B	2.8B	15.2B	25.8B	38.7B
Income Tax Expense	6.8B	4.7B	6.1B	2.4B	8.1B
Bottom Line
Net Income	2.6B	(1.4B)	14.2B	23.9B	31.9B
Earnings from Cont. Ops	2.4B	(2.0B)	10.1B	23.5B	30.7B
Earnings from Discont. Ops	(1.9B)	(1.8B)	(1.1B)	—	—
Bottom Line Net Income	2.8B	(1.4B)	14.2B	23.9B	31.9B
Per Share
Basic EPS	₩123	(₩64)	₩666	₩1,140	₩1,510
Diluted EPS	₩118	(₩64)	₩655	₩1,104	₩1,478
Revenue Per Share	₩28,686	₩28,239	₩28,096	₩25,115	₩22,633
Shares
Basic Shares Outstanding	21.4M	21.4M	21.3M	21.0M	21.2M
Diluted Shares Outstanding	22.5M	21.4M	21.7M	21.7M	21.9M
Profitability Metrics
EBITDA	(41.0B)	27.2B	45.6B	48.0B	61.8B
D&A	24.6B	23.7B	20.1B	17.6B	19.4B
EBIT	(65.5B)	3.5B	25.5B	30.4B	42.4B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026